By the end of this video, you will be able
to define drug drug interactions, DDIs. You'll be able to describe
how DDIs are identified, and be able to visualize how DDIs
affect the Cp-time curve of a drug. A drug drug interaction, or DDI,
is an interaction between a drug and another substance that prevents
the drug from performing as expected. The other substance may be a different
drug, food, or dietary supplements. Our discussion focuses on
pharmacokinetic consequences of DDIs. A DDI may cause an increase in drug
exposure, which can lead to safety risks. Alternatively, a consequence
may be reduced exposure and a loss of drug efficacy. Every DDI has a perpetrator and victim. As their names imply,
perpetrators are drugs that cause DDIs, while victims are drugs
directly affected by DDIs. Perpetrators typically cause
DDIs either by inhibition or induction of drug-metabolizing enzymes or
transporters. Assays determine the perpetrator potency
based on the drug's impact on an enzyme or transporter functional activity
using a probe substrate. Inhibitors can be reversible or
time-dependent. Different assay formats,
such as co-incubating or pre-incubating the test compound, are used
to characterize the type of inhibition. Enzyme inhibition is typically
investigated using human liver microsomes, whereas transporters and enzyme induction
is determined using either hepatocytes or cells expressing
the transporter of interest. Compounds are classified as low,
moderate, or high risk based on the potency data. This binning is useful
during the early lead optimization phase to
identify DDI liabilities. However, as the compound progresses, additional information such as
the compound's predicted clinical exposure needs to be taken into account
for calculating the clinical risk. Assessing victim DDI liability is
more involved compared to identifying perpetrators and requires the
determination of the specific enzyme or transporter in the clearance
of the compound. In addition, a thorough understanding of
the compound's elimination, clearance, and fraction metabolized or transporters is
important in estimating the DDI liability. The risk is highest if a single pathway,
such as metabolism, is responsible for
the compound's elimination, and, if metabolism is mediated
through a single enzyme. In other words,
if fraction metabolized is 100%. Victim DDI studies often involve
CYP 450 phenotyping assays, which use liver microsomes incubated
with a CYP 450 inhibitor and the test compound to estimate
the fraction metabolized. Recombinant CYP 450 enzymes can also be used to determine clearance
from each CYP isoform. Victim DDI studies, which require
a deep understanding of the compound's PK properties, are not typically
performed during early lead optimization. We can visualize pharmacokinetic drug
drug interactions with CP-time curves. Here is a typical single-dose oral CP
time-curve for drug A in a patient. We've also shown the plasma
concentrations required for efficacy and
above which toxicity is expected. Let's assume that this drug undergoes
primarily hepatic clearance. If the same patient begins to also
take a drug that inhibits drug A's metabolism, how might the new
drug A CP-time curve appear? Here we go,
the dotted line is still drug A, but it has been affected by the other drug. Hepatic clearance is lower,
so now the Cmax and area under curve are higher and
the half life is longer. A dose of drug A that was safe
is now potentially toxic. Let's now assume that our same patient,
instead of taking a metabolic enzyme inhibitor, begins to take an inducer of
the enzyme responsible for its metabolism. Here is the new drug A CP-time curve. The dotted line is still drug A, but
it has been affected by the other drug. Hepatic clearance is higher,
so now the Cmax and AUC are lower and
the half life is shorter. A dose of drug A that was efficacious
now lacks efficacy as the exposure doesn't reach the plasma
concentration efficacy threshold. These are examples of drug
drug interactions and why a drug hunting team needs to consider
whether these interactions may occur with a potential drug candidate. In particular, drugs that
are potent inhibitors of multiple metabolic enzymes or
critical drug metabolizing enzymes, especially CYP 3A4 and 3A5, CYP2D6 and CYP2C9 are less attractive as
leads due to the potential clinical DDI risk for
patients on multiple medications. We have now defined DDIs and
described how DDIs are identified. By seeing the impact that DDIs
can have upon drugs, clearance, half life, and exposure,
we now understand why DDIs are so closely monitored by drug hunting teams.